Welcome to our dedicated page for Immunocore Holdings news (Ticker: IMCR), a resource for investors and traders seeking the latest updates and insights on Immunocore Holdings stock.
Immunocore Holdings plc reports commercial and clinical developments for a biotechnology issuer whose Nasdaq-listed ADSs represent ordinary shares. The company uses its ImmTAX TCR bispecific immunotherapy platform across oncology, infectious disease and autoimmune programs, with KIMMTRAK (tebentafusp-tebn) approved for HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma in the United States, European Union, Canada, Australia and the United Kingdom.
Recurring updates cover KIMMTRAK sales and long-term survival data, lifecycle-management studies in uveal and cutaneous melanoma, the PRAME-A02 candidate brenetafusp, earlier ImmTAX candidates, HIV functional-cure research, autoimmune disease pipeline activity, financial results, investor presentations and R&D governance changes.
Immunocore (Nasdaq: IMCR) reported Q1 2026 results: KIMMTRAK net sales $106.7M (13.6% YoY) and cash, cash equivalents and marketable securities $844.9M. The company presented five-year Phase 3 OS data showing a doubling of 5-year survival (16% vs 8%; HR 0.67) and median OS 21.6 vs 16.9 months. Pipeline updates include ongoing Phase 3 trials (TEBE-AM, PRISM-MEL-301), registrational timelines in 2026, and multiple Phase 1/2 programs with data expected in H2 2026.
Immunocore (Nasdaq: IMCR) reported five-year overall survival (OS) improvements with KIMMTRAK in first-line HLA-A*02:01+ metastatic uveal melanoma patients.
KIMMTRAK achieved 5-year OS of 16% vs 8% for control (HR 0.67, 95% CI 0.54-0.85); median OS was 21.6 vs 16.9 months. Results were consistent across high tumor burden, elevated LDH, and extrahepatic disease. ctDNA clearance correlated with longer survival.
Immunocore (Nasdaq: IMCR) will present at the 25th Annual Needham Virtual Healthcare Conference with a fireside chat on April 13, 2026 at 3:00 p.m. EDT. The presentation will be webcast live and a replay will be available for a limited time via the company website.
Immunocore (Nasdaq: IMCR) will present the five-year overall survival (OS) results from the KIMMTRAK (tebentafusp-tebn) Phase 3 trial in previously untreated HLA-A*02:01 positive metastatic uveal melanoma at AACR 2026.
The oral presentation is scheduled for Sunday, 19 April 2026, 3:00–5:00 p.m. PT; a company release will follow with the full five-year OS data and additional analyses including subsequent treatments, treatment beyond progression, and prognostic factors.
Immunocore (Nasdaq: IMCR) announced management will present at multiple investor conferences in March 2026, including TD Cowen (Mar 3), Leerink (Mar 9), Barclays (Mar 10), UBS Biotech Summit (Mar 10) and Jefferies Biotech on the Beach (Mar 11).
Where relevant, presentations will be webcast live via the company’s Investors > Events & Presentations page, with replays available for a limited time.
Immunocore (Nasdaq: IMCR) reported KIMMTRAK net sales of $104.5M in Q4 2025 and $400.0M for FY2025, cash and marketable securities of $864.2M, R&D spend of $274.9M, and a FY net loss of $35.5M.
The company expects TEBE-AM enrollment to complete in 1H 2026 with topline OS data as early as 2H 2026, PRAME and HIV data in 2H 2026, and an autoimmune Phase 1 start in 1H 2026.
Immunocore (Nasdaq: IMCR) will report fourth quarter and full year 2025 financial results on Wednesday, February 25, 2026. The company will host a live teleconference and webcast at 8:00 a.m. EST (1:00 p.m. GMT) to discuss results and provide a business and portfolio update.
Investors can access the live audio webcast via the 'Events' page in the Investors section at www.immunocore.com; a replay will be available for a limited time.
Immunocore (Nasdaq: IMCR) announced an R&D leadership evolution: Dr. David Berman will depart effective 27 February 2026 and the company will not hire a direct replacement.
The company is promoting Dr. Mohammed Dar to EVP, clinical development and Mark Moyer to EVP, Chief Regulatory and Quality Officer, consolidating clinical and regulatory oversight while citing three ongoing Phase 3 trials and KIMMTRAK approval in 39 countries.
Immunocore (Nasdaq: IMCR) outlined 2026 strategic priorities at the 44th Annual J.P. Morgan Healthcare Conference, focused on expanding KIMMTRAK (tebentafusp) access, advancing three registrational Phase 3 melanoma trials (including TEBE-AM enrollment completion expected 1H 2026 with topline as early as 2H 2026) and multiple Phase 1/2 readouts in 2026 for PRAME bispecifics.
The company plans first autoimmune dosing in 1H 2026, HIV data in 2H 2026, and reported preliminary year-end 2025 cash of approximately $864 million.
Immunocore (Nasdaq: IMCR) announced management will present at two investor conferences in November 2025: a Guggenheim 2nd Annual Healthcare Innovation Conference fireside chat on Tuesday, November 11, 2025 at 3:00 p.m. EST, and a Jefferies London Healthcare Conference fireside chat on Wednesday, November 19, 2025 at 3:30 p.m. GMT.
Where relevant, presentations will be webcast live and available under Investors > Events & Presentations on Immunocore's website, with replays posted for a limited time.